$10.9 billion is the price AbbVie said on Monday it would pay for Apogee Therapeutics, a cash bid built around Apogee’s lead drug candidate, zumilokibart. The offer gives Apogee shareholders $135.11 a share and folds the biotech into AbbVie’s next-generation immunology pipeline.
AbbVie and Apogee Therapeutics
$135.11 per share values the transaction at a 49.49% premium to Thursday’s close, a gap that shows how aggressively AbbVie is bidding for the asset. Apogee shares were at $136.3 in premarket trading, slightly above the offer price and signaling that the market is pricing in either a cleaner path to completion or a better outcome for holders.
$10.9 billion in cash gives AbbVie access to zumilokibart, an experimental treatment aimed at inflammatory diseases. The candidate targets moderate-to-severe atopic dermatitis and asthma, two areas that fit squarely inside AbbVie’s next-generation immunology push and explain why the company chose to pay in cash rather than stitch together a more complex structure.
Zumilokibart and AbbVie
49.49% is a large premium for a company whose value now rests on one lead candidate, and it leaves Apogee holders with a clear comparison: the offer price versus the higher premarket trading level. For investors, that spread is the immediate tell that the deal is not just a simple headline number; it is a test of whether the buyer can secure a drug platform the market already thinks is worth more than the bid.
Monday, June 22, is the date AbbVie put the transaction on the record, and the cleanest takeaway is that the company is paying upfront for speed in immunology rather than waiting to build that profile drug by drug. The source does not say whether Apogee shareholders or regulators have signed off, so the pricing gap is the live issue sitting in front of both sides.
